by admin | Apr 19, 2024 | Article
Ontario individuals who are immunocompromised can get a fourth dose (booster) three months (84 days) after completion of the three-dose primary series. Please visit https://covid-19.ontario.ca/getting-covid-19-vaccine for more information.
by admin | Apr 19, 2024 | Article
Please visit https://www.canada.ca/en/public-services-procurement/news/2022/02/government-of-canada-signs-new-covid-19-antibody-therapy-agreement.html for details.
by admin | Apr 19, 2024 | Article
Please visit https://rheum.ca/wp-content/uploads/2022/03/FINAL-Updated-PS-on-COVID-19-Vacc-March-25_2022_for-publication.pdf for details.
by admin | Apr 19, 2024 | Article
As an initiative of the Canadian Rheumatology Association and endorsed by Lupus Canada and the Canadian Network of Improved Outcomes in SLE, the Canadian SLE Working Group has recently published new recommendations for the assessment and monitoring of lupus patients...
by admin | Apr 19, 2024 | Article
Evusheld is now approved for use in adults and children (12 years of age and older, weighing at least 40 kg) who are not currently infected with COVID-19 and have not had recent known contact with someone infected with COVID-19, and: who are immune...
by admin | Apr 19, 2024 | Article
In the most extensive study to date, GSK’s Belimumab (alongside Standard therapy) vs. placebo showed a significant improvement in LN renal response, such as renal filtration and urine protein creatinine. Moreover, Belimumab also demonstrated a favorable safety...
